Chinese investment group Fosun says it has revised an offer for Indian pharmaceutical company Gland Pharma after regulators in India held up the $1.1bn deal during a time of political discord between the two countries.
manbetx3.0 投资集团复星(Fosun)表示，已调整对印度制药商Gland Pharma的报价，此前印度监管机构在两国政治不和的背景下叫停了这笔11亿美元的交易。
您已阅读15%（294字），剩余85%（1650字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。